April 10-11, 2025 | Boston, MA USA
April 10-11, 2025 | Boston, MA USA
April 10-11, 2025 | Boston, MA USA


Arrowhead Sci-Tech Conferences & Events is pleased to announce the return of the Annual Translational Microbiome Conference in the spring of 2025. The Translational Microbiome Conference was the first microbiome conference in the field to focus on the hurdles and challenges to commercial and clinical success in the space and continues to expand on that mission yearly, bringing well considered and curated content to a diverse audience at an affordable price.

Conference Focus

Entering its 9th year in 2024, the meeting will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. Additionally, this meeting also showcases ground-breaking research being performed by leadings scientist from around the globe. Conference highlights include:

Cutting-Edge Research: Immerse yourself in the latest breakthroughs, advancements, and scientific insights in microbiome research.

Interdisciplinary Perspectives: Engage in stimulating discussions that bridge the gap between different disciplines, including microbiology, genomics, immunology and bioinformatics.

Networking Opportunities: Connect with a diverse community of researchers, scientists, and industry professionals passionate about the microbiome.

Poster Sessions and Oral Presentations: Showcase your own research findings or gain inspiration from the work of others through interactive poster sessions and oral presentations.

Technology and Methodology Showcase: Explore cutting-edge technologies, innovative methodologies, and analytical tools that are revolutionizing microbiome research.

Translational Applications: Discover how microbiome research is shaping our understanding of human health, disease, and therapeutics. Gain insights into the development of microbiome-based interventions.

Why You Should Attend

Partnering Software & Meetings

Partnering Software & Meetings

Easily schedule meetings with our partnering system in order to maximize your time at the event. Schedule one-to-one meetings in advance and stay connected after the event.
Industry-Leading Speaking Faculty

Industry-Leading Speaking Faculty

Our tightly curated content provides tangible and useful insights to how your peers are addressing their scientific, clinical and commercial approach to the space.
Network With Industry Colleagues

Network With Industry Colleagues

One-to-One meeting space, breakfasts, extended breaks, luncheons and receptions provide attendees with multiple opportunities to connect with colleagues in the space.
Exhibitors/Service Providers

Exhibitors/Service Providers

Meet with and/or re-connect with exhibitors and service providers and learn about the latest tools and resources driving the field of microbiome science.

2024 Exhibitors and Sponsors

Conference Topics & Themes

  • Mapping the microbiome at the molecular level
  • Cancer and the microbiome
  • Microbial dysbiosis and various disease states
  • Type 1 diabetes, obesity and the gut microbiome
  • The oral microbiome and its correlation with chronic systemic conditions
  • Diet and the microbiome-gut-brain axis
  • Synthetic biology-based microbiome therapeutics
  • The infant gut microbiome
  • Biomarker discovery for microbiome-related diseases
  • Clinical metagenomics for precision infectious disease diagnostics
  • Bioinformatic tools and AI to support the use of microbial genomic data
  • Precision microbiome analysis
  • Women's health and the microbiome
  • Regulatory guidelines for microbiome based therapeutics
  • Standards for microbiome measurements

2024 Featured Speakers

Past Exhibitors and Sponsors

Conference Agenda

We are currently in the process of revising the following agenda for our newly announced Virtual Conference, taking place on April 21-24, 2020. New dates and times for the below presentations will be announced very soon.


DAY ONE - Tuesday, April 21, 2020

7:15 am Registration/Continental Breakfast

7:50 am Chair’s Opening Remarks
Mollie Roth, J.D., Executive Director, The Microbiome Coalition

8:00 am Designing Living Diagnostics and Therapeutics for the Microbiome
We can engineer the microbiome to report on the health of the gut microbiome and report on the presence of pathological states such as inflammation. These sensor bacteria can also be engineered to deliver therapeutics on demand. We also use targeted bacteriophage to shape and program the gut microbiome. In doing so, we have developed novel targeted therapeutic strategies.
Pamela Silver, Ph.D., Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology, Harvard Medical School

8:30 am Targeted Delivery and Controlled Release of Bacteriophages and Bacteriocins
This talk will present scalable approaches available for micro- and nano- encapsulation of bacteriophages and bacteriocins. In vitro and in vivo results from studies in mice and poultry will be presented showing the benefits of targeted delivery and controlled release of biotherapeutics to improve bioavailability and overcome environmental stresses including gastric acidity and enzymatic degradation.
Danish Malik, Ph.D., Senior Lecturer, Chemical Engineering Department, Loughborough University

9:00 am Challenges in Commercially Developing Phage Therapies to Target Drug-Resistant Bacteria
Increasing prevalence and severity of multi-drug-resistant bacterial infections requires novel antibacterial strategies. One possibility is a renewed approach to ‘phage therapy’. This presentation concerns the discovery of phages (bacteria-specific viruses) that associate with virulence factors of target bacterial pathogens. Dr. Turner will present empirical support for this hypothesis, and will showcase results of FDA approved emergency treatment in humans, harnessing various phages that drive evolutionary trade-offs in bacterial pathogens.
Paul Turner, Ph.D., Rachel Carson Professor of Ecology & Evolutionary Biology, Yale University

9:30 am Use of Phage Cocktail in Chronic Disease Indications (non-CME presentation)
In this presentation, Mr. Oron will discuss the following:
♦ A clinical trial for evaluating BX001 for acne prone skin
♦ BX002 targeting a novel proinflammatory target in inflammatory bowel disease
Assaf Oron, Chief Business Officer, BiomX

10:00 am Refreshment Break/Poster and Exhibit Viewing

10:30 am Challenges in the Use of Phage as Treatment Options as well as Elucidating Their Role in Disease (non-CME presentation)
Bacteriophages, viruses specific to bacteria, regulate trillions of bacteria found in the human gut which constitute the microbiome in a complex dance that involves a molecular signaling that is only just beginning to be revealed. EpitopeRX is working to build a platform for the use of the knowledge of bacteriophage for a range of constructs - from unique vaccines to funding research into phage-bacterial etiology of several chronic diseases.
Jonathan Merrill, MD, Chief Executive Officer, Epitope Rx

11:00 Viral Metagenomics: Identifying the Needles in the Haystack and Unlocking Opportunities for Discovery (non-CME presentation)
Applications of phage therapy and recent publications highlighting the discovery potential inherent in the human virome and have focused new attention on the field of viral metagenomics. From identifying risk factors and discovering potential biomarkers to creating novel and highly targeted therapies, viruses represent a largely untapped resource for discovery, diagnostics, and therapeutics. Novel sample collection strategies, sequencing approaches, and analytical tools will help to drive discovery in this space.
Emily Hollister, VP Information Technologies and Analytics, Diversigen

11:30 Panel Discussion: Hurdles and Challenges in Developing Phage Therapies (non-CME panel)
Moderator: Mollie Roth, J.D., Executive Director, The Microbiome Coalition
Danish Malik, Ph.D., Senior Lecturer, Chemical Engineering Department, Loughborough University
Paul Turner, Ph.D., Rachel Carson Professor of Ecology & Evolutionary Biology, Yale University
Assaf Oron, Chief Business Officer, BiomX
Emily Hollister, VP Information Technologies and Analytics, Diversigen

12:15 pm Luncheon

1:15 pm A Microbiome Platform for the Development of Personalized Nutrition and Therapeutics (non-CME presentation)
Over the past decade DuPont Nutrition and Biosciences has built the expertise and technology to modulate the microbiome through leadership in probiotic and prebiotic development, enzyme engineering, clinical studies, and product commercialization. DuPont’s core competencies in microbiome science will be introduced along with key initiatives positioning DuPont as a strong partner and innovator in the field of microbes for nutrition, health, and wellness.
Charles R. Budinoff, Ph.D., Strain Discovery and Microbiome Science Leader, DuPont Nutrition & Biosciences

1:45 pm Gut Microbiome Perturbation is Associated with Vaccine Hypo-Responsiveness (non-CME presentation)
Emerging evidence suggests that antibiotics have direct and indirect effects on mucosal and systemic immunity. However, the microbiome-mediated effects of antibiotic use on vaccine responses are not fully characterized. Using translational pre-clinical models including germ-free and antibiotic treated mice, we show that microbiome perturbation leads to reduced vaccine outcome. Current mechanistic studies are aimed at investigating microbial and immune pathways that are differentially modulated in germ-free & antibiotic treated mice. An increasingly detailed understanding of host and microbiome-derived factors that are critical for optimal outcome of vaccines will significantly influence the future design of vaccines & immunotherapies.
Gokul Swaminathan, Ph.D., Associate Principal Scientist, Merck Exploratory Science Center

2:15 pm Harnessing the Power of Metabolomics for Microbiome Analysis(non-CME presentation)
Metabolomics can deliver uniquely valuable biological insights in microbiome research that are otherwise unseen through other technologies. Unlike genomic sequencing and other ‘omics, metabolomics reveals in vivo microbiome function before, during or after therapeutic intervention, to better inform drug development decisions. Metabolomics allows researchers to characterize microbial-derived biochemicals within the gut, as well as those that enter the host bloodstream, potentially crossing the gut-brain axis and into other organs. This talk will review recent advances in metabolomics technologies that have led to improved understanding of the role of the microbiome in human health and disease.
Priya Ramamoorthy, Ph.D., Senior Study Director, Discovery and Translational Sciences, Metabolon

2:45 Panel Discussion: Looking into a Crystal Ball: What Does the Future of Microbiome Therapeutics Hold for Us in the Next 5 years? (non-CME panel)
We all expect the excitement of microbiome therapeutics to continue for decades to come. In this panel, we will hear from experts paving the way from the investment and big pharma sectors. The panel will explore:
♦ Key lessons learned from the past 5 years in microbiome R&D translating to the clinic
♦ Predictions of what successful microbiome therapeutics will look like in the next 5 years
♦ Research, regulatory, reimbursement and business challenges that need to be overcome and opinions on the way forward
Moderator: Manoj Dadlani, Chief Executive Officer, Cosmos ID
Denise Kelly, Ph.D., Investment Advisor, Seventure Partners
Dirk Gevers, Ph.D., Global Head, Microbiome Solutions, World Without Disease Accelerator, Janssen Human Microbiome Institute
Arpita Maiti, Ph.D., Executive Director & Global Head, Emerging Science & Innovation Lead – Inflammation & Immunology, Pfizer

3:30 pm Refreshment Break/Poster and Exhibit Viewing

4:00 pm Optimized Microbiome Workflow: Towards Microbiome-Based Diagnostics & Therapeutics Solutions (non-CME presentation)
The human gut microbiome has been described as the most complex ecosystem on earth. As microbiome research evolves, more and more health conditions are being linked to an unbalanced microbial composition. As microbiome research gradually moved from association to causation, the complexity increases as we move from genome to transcriptome, proteome, metabolome and beyond. Because the methods and tools to make measurements of the microbiome vary widely, results produced by different laboratories are often not comparable. Standards and validated protocols are crucial for gaining a full picture of the microbiome’s basic features, as well as translating it into therapeutic strategies.
Michal Daniely, Ph.D., Research and Development Director, MilliporeSigma

4:30 pm Ultra-high Resolution Microbiomics and Derived Functional Insights as a Tool to Maximize the Outcome in Clinical Studies (non-CME presentation)
Henrik Bjorn Nielsen, Ph.D., Chief Scientific Officer, Clinical Microbiomics

5:00 pm BARDA DRIVe: Partnering with the USG on Health Security Innovations (non-CME presentation)
BARDA provides a comprehensive integrated portfolio approach to the advanced R&D and acquisition of medical countermeasures (vaccines, therapeutics, and diagnostics) against public health emergencies that involve CBRN threats, pandemic influenza, and emerging infectious diseases. Ms. Boston’s most recent work with BARDA’s Division of Research, Innovation and Ventures (DRIVe) aims to revolutionize the current state of health security products and technologies by supporting promising, early-stage innovations with a venture-capital approach and commercial best practices.
Donna Boston, Program Manager, Division of Research, Innovation & Ventures (DRIVe), Biomedical Advanced R&D Authority (BARDA), Assistant Secretary for Preparedness & Response (ASPR), US Dept. of Health & Human Services (HHS)

5:15 End of Day's Proceedings

DAY TWO – Wednesday, April 22, 2020

7:15 am Continental Breakfast

7:50 am Chair’s Opening Remarks
Mollie Roth, J.D., Executive Director, The Microbiome Coalition

8:00 am Funding Startups in Women's Healthcare
In spite of the billions of dollars in funding across the microbiome space, there is a traditional underwhelming response by investors in women's health opportunities. This presentation will discuss the perceived causes for this disparity, the sectors typically affected, and the recent promising increase in interest in the "femtech" space in terms of renewed funding. Given the latest predictions of reaching $50B in investment by 2025 we’ll discuss how our company managed to fund our development and what pitfalls and successes we encountered in the process.
Rachel Teitelbaum, Ph.D., Chief Executive Officer, Hervana

8:30 am The Use of Wild Mouse Models to Further Microbiome Research
Laboratory mice are paramount for understanding basic biological phenomena but also have limitations in preclinical studies. Based on the concept that natural microbiota co-evolved with their respective hosts under evolutionary pressure of common environmental immune stimuli, Dr. Rehermann will describe and discuss new mouse models that combine the natural microbiota of wild mice with the tractable genetics of laboratory mice. Wild mouse microbiota are stable over multiple generations in the laboratory mouse colonies, promote host fitness and disease resistance and increase the translatability of immunological results from preclinical studies to humans.
Barbara Rehermann, MD, Section Chief, Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health

9:00 am Microbiome Therapeutics at Takeda: Leveraging External Partnerships to Explore Multiple Modalities and Hypothesis-Driven Approaches (non-CME presentation)
Henry Haiser, Ph.D., Associate Scientific Director, GI Drug Discovery, Microbiome Sciences, Takeda

9:30 am Targeting the Brain-Gut-Microbiome Axis by ImmuneBiotics, a New Therapeutic Avenue for Management of Autoimmunity (non-CME presentation)
This presentation will navigate through the translational, clinical, and manufacturing challenges of microbiome-based therapeutics. Dr. Lavasani will cover the following:
♦ Microbiota dysbiosis and intestinal barrier dysfunction in Irritable Bowel Syndrome and multiple sclerosis
♦ Brain-gut-microbiome axis; potential therapeutic targets and probiotic treatments
♦ Designing multi-targeted therapeutic microbial consortium; translational success for GutMagnificTM in management of IBS
♦ ImmuneBioticsTM, new generation of probiotic products designed to boost the immunotherapy treatments
Shahram Lavasani, Ph.D., Founder, Chief Executive Officer, Chief Scientific Officer, Immune Biotech

10:00 am Refreshment Break/Poster and Exhibit Viewing

10:30 am Standards for Microbiome and Metagenomics
In spite of the huge potential impact of microbiome science, current measurement capabilities are insufficient, particularly for translating discoveries and correlations observed in the lab into commercially viable products and services that improve our quality of life. Data are difficult to compare between experimenters, laboratories, or institutions. Emerging capabilities (e.g., next generation sequencing, metabolomics) are new and not fully characterized for microbiome investigations. Reference samples (i.e., for calibration or quality control) that mimic the complexity of naturally occurring communities are not available. Bioinformatic analysis packages and reference databases remain incomplete.
Scott Jackson, Ph.D., Group Leader, Complex Microbial Systems, NIST (National Institute of Standards & Technology)

11:00 Panel Session: Challenges and Solutions in the Development and Application of Microbiome Standards (non-CME panel)
While research on the microbiome has provided valuable insights into how microbial communities shape human health and disease, there are still many outstanding questions left to be answered. Join us for a collaborative discussion on the hurdles that microbiome researchers face during each stage of the workflow, challenges and solutions in the development and application of microbiome standards, and current gaps and future trends in microbiome research.
Moderator: Briana Benton, Technical Manager, American Type Culture Collection (ATCC)
Nick Greenfield, Founder and CEO, One Codex
Sam Minot, Ph.D., Staff Scientist, Microbiome Research Initiative, Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Center
Gokul Swaminathan, Ph.D., Associate Prinicipal Scientist, Merck Exploratory Science Center
Scott Jackson, Ph.D., Group Leader, Complex Microbial Systems, NIST (National Institute of Standards & Technology)

11:45 ACS Extramural Research: Portfolio, Programs and Funding Opportunities
Lynne Elmore, Ph.D., Director, Translational Cancer Research Program, American Cancer Society

12:00 pm Luncheon

1:00 pm Gut Microbiome and Intestinal Permeability as the Novel Criteria for Toxicological Risk Assessment
Exposure to ingested xenobiotics including drugs, as well as, chemical additives/contaminants on edible items could lead to dysbiosis in the gastrointestinal tract. A comprehensive understanding of the toxicologic effects of such exposure on the intestinal microbiome is crucial when evaluating the safety of these products since they play an important role in maintaining health. In this presentation, Dr. Khare will discuss the challenges and opportunities to establish gut microbiota, intestinal permeability - xenobiotic interactions as novel criteria to include in toxicological risk assessments.
Sangeeta Khare, Ph.D., Research Microbiologist, Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration

1:30 pm Development, Validation, and Unique Applications of Species-specific Microbiome Assay & Database that Together Provide True Pan-Domain Molecular Diagnostics
Garth Ehrlich, Ph.D., Professor of Microbiology & Immunology, Professor of Otolayngology - Head & Neck Surgery, Drexel University College of Medicine

2:00 pm Data Driven Design of Microbiome-Based Therapeutics and Diagnostics Using Gene-Level Metagenomics
The human microbiome contains an incredibly diverse collection of microbes which can have a large impact on host health and disease. Surveys of the microbiome have identified broad associations with disease, but have yet to robustly identify individual strains with probiotic potential. Dr. Minot will discuss innovations in gene-level metagenomic analysis which may enable an entirely new approach to the design of microbiome-based therapeutics and diagnostics.
Sam Minot, Ph.D., Staff Scientist, Microbiome Research Initiative, Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Center

2:30 pm A Survivor’s Perspective: The Bigger Picture of the Patient Journey
Too often, manufacturers of therapeutics forget that the patient is more than simply someone taking a pill, but a person on an often long and arduous journey; a journey in which a therapeutics manufacturer can and often should become more than simply a supplier, but a trusted partner. In this presentation, Nancy C. Caralla, Founder of the C Diff Foundation and three-time C. difficile infection survivor, will share first-hand knowledge of one patient's journey that will bring needed perspective to the audience and new insights that should be front of mind for anyone developing new microbiome therapies.
Nancy Caralla, Founding President, Executive Director, C Diff Foundation

3:00 pm Metagenomics as a Vital Tool for the Development of Diagnostics for Emerging Infectious Diseases
Urethritis is a common male genitourinary tract syndrome, up to 50% of cases are of unknown etiology and diagnosed with idiopathic urethritis (IU). Dr. Toh's team used parallel shotgun metagenomic and 16S sequencing approaches to compare the urethral microbiomes of large cohorts of healthy men, men with IU, and of men with urethritis of known etiologies. Their results indicate novel pathogens and atypical presentations of known pathogens contribute to IU, demonstrate the power of metagenomics for defining etiology in urogenital tract syndromes of unknown origin, and demonstrate how metagenomics data-sets can be rapidly harnessed to develop diagnostics for emerging infectious diseases.
Evelyn Toh, Ph.D., Research Scientist, Department of Microbiology & Immunology, Indiana University School of Medicine

3:30 pm Refreshment Break/Poster and Exhibit Viewing

4:00 pm Considerations for Gut-Based Brain Research
Much research in neuroscience has neglected the rest of the body, until recently, when the “gut-brain axis” has come to light. From the perspective of a neuroscientist, this talk will cover considerations in clinical trials and basic science research to incorporate questions about the gut to more holistically assess neurological disease. Lessons learned from our research on Alzheimer's disease will serve as a concrete reference.
Amy Feehan, Ph.D., Research Scientist, Ochsner Health System

4:30 Gut Microbiota Induces Anti-Tumor Immunity Restricting Tumor Growth – The RNF5-UPR-Inulin Journey
This presentation will highlight studies in which we have demonstrated the importance of the ubiquitin ligase RNF5 in the control of gut microbiota composition with a concomitant effect on anti-tumor immunity and tumor growth inhibition. The role of Unfolded Protein Response in RNF5-mediated changes in gut microbiota and anti-tumor immunity will be discussed, and finally, the identification of prebiotics that are capable of inducing anti-tumor immunity and restrict tumor growth.
Ze'ev Ronai, Ph.D., Professor, Sanford Burnham Prebys Medical Discovery Institute

5:00 pm Gut Microbiota Mediates the Vascular Beneficial Effects of Dietary Anthocyanins
Clinical studies support the cardiovascular benefits of berry anthocyanins. This presentation will focus on how dietary blueberry anthocyanins shift the composition and functional potential of the gut microbiome and improve vascular health in preclinical models. This presentation will also discuss the role of the gut microbiome and anthocyanin-derived microbial metabolites in mediating the vascular effects of blueberries.
Anandh Babu Pon Velayutham, Ph.D., Associate Professor, Nutrition & Integrative Physiology, University of Utah

5:30 pm End of Day's Proceedings

DAY THREE – Thursday, April 23, 2020

7:00 Continental Breakfast

7:45 am Microbiome Funding Opportunities with the ISS
Rachel Clemens, Ph.D., Commercial Innovation Manager, Life Science Lead, ISS US National Lab, Center for Advancement in Science in Space

8:00 am Long-Term Benefit of Microbiota Transfer Therapy on Autism Symptoms and Gut Microbiome
Over the last couple of decades, autism spectrum disorders (ASD) have become substantially prevalent, but the etiology of these complex neurobiological disorders remain poorly understood. Accumulating evidence revealed that children with ASD have disrupted gut microbiome, which suggests that modifying it is a potential route to improve ASD behavioral symptoms. Thus, we designed and performed an open-label trial of Microbiota Transfer Therapy (MTT) that combined antibiotics and fecal microbiota transplant. Notably, children with ASD experienced significant improvements in GI symptoms and autism-related symptoms, even two years after treatment was completed. Their gut microbiome was transformed toward a healthy one, including significant increases in bacterial diversity and relative abundances of Bifidobacteria and Prevotella. Our observations support MTT as a promising safe and efficient approach to change the gut microbiome and improve GI and behavioral symptoms of ASD.
Dae-Wook Kang, Ph.D., Assistant Professor, Department of Civil and Environmental Engineering, University of Toledo

8:30 am Reverse Translation in the Microbiome: Leveraging Clinical Data to Identify Microbes Driving Patient Outcomes (non-CME presentation)
Data from whole-community microbial transfers in patients can provide proof-of-concept to retire risk early in the development of novel microbial therapies. Leveraging data from thousands of patients, Finch has developed a Human First Discovery platform to rapidly translate clinical data into new products in diverse therapeutic areas ranging from ulcerative colitis to autism spectrum disorder.
Sonia Timberlake, Ph.D., Vice President of Research, Finch Therapeutics

9:00 am A Translational Approach to Exploiting the Gut-Brain Axis in Autism Spectrum Disorder (non-CME presentation)
This talk will present the approach Axial Biotherapeutics is taking to develop novel treatments for problematic symptoms that occur in people with autism spectrum disorder (ASD). Axial is evaluating AB-2004 in a clinical setting based on a clear mechanism of action hypothesis supported by translationally relevant preclinical data.
A. Stewart Campbell, Ph.D., Vice President, Early Stage Development, Axial Biotherapeutics

9:30 am Bacteriome and Mycobiome Interactions: A Model for Promoting Human Health and Combating Disease
It is now well established that the bacterial and fungal communities residing in and on our body play a significant role in our health and disease status. The next step is how we can modulate these communities to maintain balance leading to better wellness. In this presentation Dr. Ghannoum will use his team’s discoveries in Crohn’s disease (CD) patients as a model of how to achieve this goal.
Mahmoud Ghannoum, Ph.D., EMBA, Professor, Department of Dermatology, Case Western Reserve University, University Hospitals Cleveland Medical Center

10:00 am Refreshment Break/Poster and Exhibit Viewing

10:30 am Lupus and Dysbiosis in the Gut Microbiome: Cause or Effect or Both?
Throughout our lives we are immersed in, and colonized by, immense and complex microbial communities. Yet, at times imbalances within microbiota contribute to metabolic and immune regulatory abnormalities that underlie the development of inflammatory and autoimmune diseases. Recent progress in investigations of the microbiome are beginning to illuminate aspects of the pathogenesis of Systemic Lupus Erythematosus, and may suggest that interconnections with specific disease-associated patterns of dysbiosis within gut communities could be bidirectional and mutually reinforcing.
Gregg Silverman, MD, Professor of Medicine & Pathology, New York University School of Medicine

11:00 am Science to Market: From a Bacterial Strain to a Skincare Product (non-CME presentation)
The scientific community continues to demonstrate the functional role of the human gut and skin microbiome as an inspirational source for future therapeutics, food supplements and cosmetics. In recent years, skin has evolved as one of the most extensively described tissue regarding microbiome diversities linked to host physiology, age, environmental exposure, and diseases. Moreover, the role of the skin microbiome has been validated by clinical results with respect to atopic dermatitis, acne, dandruff and seborrheic dermatitis. Atopic xerosis and dandruff are both sub-inflammatory skin disorders driven by immune dysfunctions and are characterized from early stages by itch and delay in healing. As recently described, these two disorders are associated with specific dysbiosis of the skin microbiome with altered microbial diversity characterized by excess of Staphylococcus spp. or Malassezia spp., respectively. Recent research and new results of the clinical evaluation of skin microbiome- based traitements with bacterial strains on these disorders are discussed and will serve as guidance for scientists from the industrial and academic community to create new generation of microbiome-targeted skincare with predictable modes of action and consistent clinical outcomes.
Cécile Clavaud, Ph.D., Project Leader in Skin Microbiome, L'Oreal Advanced Research, L'Oreal

11:30 am Panel Session to be Announced

12:15 pm Luncheon

1:15 pm A New Era in Microbiome Research: The Prospector Array Based Microbial Cultivation and Screening Platform (non-CME presentation)
Deep insights into microbiome structure and function are the foundation for microbial applications in human health, agriculture, environment, and industry. Antiquated, labor intensive methodologies currently used to cultivate microbes are a significant barrier to access microbes from microbiome samples for research and product development. The Prospector platform with its highly dense array of > 6000 nanoscale cultivation chambers integrated with an instrument that automates the cultivation workflow can enable researchers to isolate 1000s of microbes in parallel for microbiome analysis at an unprecedented scale.
Peter Christey, Ph.D., CEO and Co-Founder, General Automation Technology Labs (GALT)

1:45 pm Act Locally, Think Globally: Understanding Microbiome-Related Modulation of Systemic Immune Responses (non-CME presentation)
Interactions between the immune system and the gut microbiome have a pivotal role on the efficacy of cancer immunotherapy. A growing body of knowledge shows that microbiome diversity, with enrichment of specific microbial species, is the strongest predictor of checkpoint inhibitor response. However, the link between specific enteric populations and the immune response within the tumor microenvironment is poorly understood. We are performing comprehensive and integrated analysis of the microbiome populations, immune system modulation and changes on inflammatory markers and metabolic profiles and its relationship with tumor growth and ICI efficacy. In addition, we are expanding this approach to understand the relevance of the microbiome/immune system interaction in other relevant therapeutic areas like liver diseases or diabetes.
Sara Ferrando Martinez, Ph.D., Research Scientist, AstraZeneca

2:15 pm Immunotherapeutic Approaches to Selective Modification of Microbiome Structure and Function (non-CME presentation)
This presentation will highlight the ways that conventional antibody science has advanced conventional organ/system research and then outline ways in which we can now intervene quite specifically in dysbiosis-driven pathogenesis. Several examples of emerging discrete pathways that are enlightening us will be presented on colorectal cancer pathogenesis and undesirable drug metabolism of levodopa, and use these as examples of direct application of our IgY (avian antibody) technology.
Julius Goepp, MD, Chief Executive Officer, Scaled Microbiomics

2:45 pm Refreshment Break/Poster and Exhibit Viewing

3:15 pm Progress Towards Standardizing Metagenomics: Application of Metagenomic Reference Materials to Develop a Reproducible Microbial Lysis Methodology with Minimum Bias (non-CME presentation)
The rapid growth of metagenomics research has contributed to a lack of reproducibility between different methods and laboratories, which risks limiting our ability to compare between studies and decreases confidence in previous conclusions. To address the diversity of methods available, Dr. Weinstein and his team have sought to compare the performance of many commercially- and academically-sourced lysis protocols. The methods were evaluated using mock microbial community standards with defined composition and known manufacturing tolerances to serve as a ground truth for the measurement. In order to facilitate comparisons, they developed the Measurement Integrity Quotient (MIQ), providing a single, easy to understand numerical score that describes the accuracy of an observed composition relative to a known composition standard. Utilizing this method, they compared the effects of many different variables on lysis efficiency, including differences between thermal, enzymatic, and mechanical (bead) lysis as well as minor changes within a method, including over 40 different bead material/size combinations and cell disruptor type/intensity/run time combinations. Additionally, several replicates of typical sample types were tested with different lysis methods with replicates at different laboratories for over 1500 samples tested. This research will be discussed.
Michael M. Weinstein, Ph.D., Scientist, Zymo Research

3:45 pm Data-Driven Personalized Nutrition to Modulate Gut Microbiome Functions: Towards Prevention of Chronic Diseases (non-CME presentation)
Gut microbiome dysbiosis has been studied in the context of taxonomy, but research in this area has yielded very little actionable information. Viome focuses on the microbial functional dysbiosis, which we have tied to several chronic diseases. Not only is the functional dysbiosis more predictive of chronic diseases, it is very actionable. Microbial functions are mostly determined by the molecules in the foods we consume. Therefore, microbial functions can be modulated by adjusting each person's diet to support healthy microbial functions, and shut down those associated with disease. Viome's systems biology platform and results from several large studies will be presented.
Momo Vuyisch, Ph.D., Chief Scientific Officer, Viome

4:15 End of Conference

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at

Contact Us

Arrowhead Sci-Tech Conferences & Events
PO Box 96
7730 Laredo Drive, #96
Chanhassen, MN 55317


Organized By

Join Our Linked In Group & Twitter Feed